GNOM vs. IDNA
Compare and contrast key facts about Global X Genomics & Biotechnology ETF (GNOM) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA).
GNOM and IDNA are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GNOM is a passively managed fund by Global X that tracks the performance of the Solactive Genomics Index. It was launched on Apr 5, 2019. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. Both GNOM and IDNA are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GNOM or IDNA.
Key characteristics
| GNOM | IDNA | |
|---|---|---|
| YTD Return | -13.26% | -3.22% |
| 1Y Return | -19.53% | -5.97% |
| 3Y Return (Ann) | -23.99% | -21.57% |
| Sharpe Ratio | -0.69 | -0.26 |
| Daily Std Dev | 29.15% | 25.12% |
| Max Drawdown | -68.54% | -68.26% |
| Current Drawdown | -64.04% | -59.01% |
Correlation
The correlation between GNOM and IDNA is 0.90, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
GNOM vs. IDNA - Performance Comparison
In the year-to-date period, GNOM achieves a -13.26% return, which is significantly lower than IDNA's -3.22% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
GNOM vs. IDNA - Expense Ratio Comparison
GNOM has a 0.50% expense ratio, which is higher than IDNA's 0.47% expense ratio.
Risk-Adjusted Performance
GNOM vs. IDNA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GNOM vs. IDNA - Dividend Comparison
GNOM has not paid dividends to shareholders, while IDNA's dividend yield for the trailing twelve months is around 1.08%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% | 0.00% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.08% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
Drawdowns
GNOM vs. IDNA - Drawdown Comparison
The maximum GNOM drawdown since its inception was -68.54%, roughly equal to the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for GNOM and IDNA. For additional features, visit the drawdowns tool.
Volatility
GNOM vs. IDNA - Volatility Comparison
Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 8.32% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 5.36%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.